Skip to main content
. 2020 Aug 25;10:1455. doi: 10.3389/fonc.2020.01455

Figure 1.

Figure 1

(A) Distribution of sPD-L1 concentrations prior to the initiation of EGFR-TKI treatment according to therapeutic responses. (B) Distribution of sPD-L1 concentrations 1 month after initiating EGFR-TKI treatment according to therapeutic responses. (C) sPD-L1 concentrations at pre-treatment and on-treatment in whole patient group. (D) sPD-L1 concentrations at pre-treatment and on-treatment in patients with PR. (E) sPD-L1 concentrations at pre-treatment and on-treatment in patients with SD or PD (Results are presented as mean ± SD. **P < 0.01; NS, Not Significant).